Convalescent plasma may be considered in COVID-19 patients with moderate disease who are not improving (oxygen requirement is progressively increasing) despite use of steroids, noted a one-page advisory issued by the Central Drugs Standard Control Organisation (Biological Division), here on Wednesday.
Also read: Study on plasma therapy is ongoing: ICMR
The Health Ministry last week released guidelines on clinical management protocol for COVID-19 where certain therapies were indicated for use as investigational therapies, in which convalescent plasma by plasmapheresis has been indicated as “Off Label” in COVID-19 patients’.
The organisation has specified special prerequisites while considering convalescent plasma — ABO compatibility and cross matching of the donor plasma, recipient should be closely monitored for several hours post transfusion for any transfusion related adverse events and use should be avoided in patients with IgA deficiency or immunoglobulin allergy.
The dose is variable ranging from 4 to 13 ml/kg, usually 200 ml single dose, given slowly over not less than 2 hours, it added.
You have reached your limit for free articles this month.
To get full access, please subscribe.
Already have an account ? Sign in
Show Less Plan
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Faster pages
Move smoothly between articles as our pages load instantly.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Personalised recommendations
A select list of articles that match your interests and tastes.
Briefing
We brief you on the latest and most important developments, three times a day.
*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.
A letter from the Editor
Dear reader,
We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.
Support Quality Journalism
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
